News - Dynavax Technologies


Current filters:

Dynavax Technologies

Popular Filters

Dynavax withdraws European MAA for Heplisav


US biotech firm Dynavax Technologies says it has withdrawn the European Marketing Authorization Application…

Anti-viralsBiotechnologyDynavax TechnologiesEuropeHeplisavRegulationVaccines

Modest growth expected for hepatitis B vaccine market

Modest growth expected for hepatitis B vaccine market


The global hepatitis B virus (HBV) vaccine market value will experience modest growth over the coming…

Anti-viralsDynavax TechnologiesHeplisavHexyonMarkets & MarketingPharmaceuticalSanofiSanofi Pasteur MSDVaccines

Negative FDA news for AVEO's tivozanib and Dynavax' hep B vaccine


US biotech firm AVEO Oncology (Nasdaq: AVEO) says that it has received a complete response letter from…

Anti-viralsAstellas PharmaAVEO OncologyBiotechnologyDynavax TechnologiesHeplisavNorth AmericaOncologyPharmaceuticalRegulationtivozanibVaccines

FDA delays approval of Dynavax' Heplisav, issuing CRL


Dynavax Technologies ( Nasdaq: DVAX) saw its shares plunge as much as 38% to $1.84 in pre-market trading…

Anti-viralsBiotechnologyDynavax TechnologiesHeplisavNorth AmericaRegulationVaccines

EMA accepts Dynavax' filing for hep B drug Heplisav


US biotech firm Dynavax Technologies (Nasdaq: DVAX) revealed yesterday that the European Medicines Agency…

Anti-viralsBiotechnologyDynavax TechnologiesEuropeHeplisavRegulationVaccines

AstraZeneca takes option on Prosidion diabetes assets; advances asthma drug


Looking to expand its R&D pipeline in the face of several recent product failures and facing a “patent…

DiabetesDynavax TechnologiesLicensingPharmaceuticalProsidionResearchRespiratory and Pulmonary

Back to top